Antithrombotic therapy in patients undergoing percutaneous coronary intervention

Chest

Volumn 119, Issue , 2001, Pages 321S-336S

  Popma, J J ^a   Ohman, E M ^a   Weitz, J ^a   Lincoff, A M ^a   Harrington, R A ^a   Berger, P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CIPROSTENE; CLOPIDOGREL; CORN OIL; DEXTRAN 40; DIPYRIDAMOLE; DOCOSAHEXAENOIC ACID; ENOXAPARIN; EPTIFIBATIDE; GLUCOSE; HEPARIN; HIRUDIN; HIRULOG; ICOSAPENTAENOIC ACID; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; OLIVE OIL; OMEGA 3 FATTY ACID; PHENPROCOUMON; PROSTACYCLIN; SULOTROBAN; TICLOPIDINE; TIROFIBAN; VAPIPROST; WARFARIN;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; NEUTROPENIA; PRIORITY JOURNAL; RESTENOSIS; SKIN MANIFESTATION; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; STENTS; THROMBIN;

EID: 0035125034     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.321s     Document Type: Article

References (134)

1. Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty
2. Evolving trends in interventional device use and outcomes: Results from the National Cardiovascular Network database
3. Reduction in angioplasty complications after the introduction of coronary stents: Results from a consecutive series of 2242 patients
4. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease
5. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
6. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
7. Relation between activated clotting time during angioplasty and abrupt closure
8. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty
9. Antiplatelet agents are effective in reducing the immediate complications of PTCA: Results from the ticlopidine multicenter trial
10. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty
11. A randomized trial of aspirin in PTCA: Effect of high versus low dose aspirin on major complications and restenosis
12. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
13. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures
14. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty: Initial results with a balloon-expandable, stainless steel design
15. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty
16. New challenges in coronary stenting
17. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents
18. Preliminary experience with intravascular ultrasound guided Palmaz-Schatz coronary stenting: The acute and short-term results on a consecutive series of patients
19. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance
20. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
21. A randomized trial comparing three drug regimens to prevent thrombosis following elective coronary stenting
22. Pretreatment with ticlopidine reduces non-Q-wave myocardial infarctions following intracoronary stenting
23. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stoke in high-risk patients: Ticlopidine Aspirin Stoke Study Group
24. Ticlopidine and severe aplastic anemia
25. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events: The Ticlopidine Aspirin Stroke Study
26. Thrombotic thrombocytope nic purpura related to ticlopidine
27. Ticlopidine and thrombotic thrombocytopenic purpura
28. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
29. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
30. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events
31. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
32. Clopidogrel versus ticlopidine after intracoronary stent placement
33. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
34. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
35. Use of clopidogrel in coronary stenting: What was the question?
36. Hemolytic uremic syndrome associated with clopidogrel
37. Thrombotic thrombocytopenic purpura associated with clopidogrel
38. Comparison of cilostazol versus ticlopidine therapy after stent implantation
39. Usefulness of cilostazol versus ticlopidine in coronary artery stenting
40. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction
41. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty
42. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: Frequency, prediction, clinical course, management and follow-up
43. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic, and therapeutic profile
44. Platelet activation during coronary angioplasty in humans
45. Cyclic flow variations after coronary angioplasty in humans: Clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody
46. Receptor-specific antiplatelet therapy
47. New perspectives in cell adhesion: RGD and integrins
48. The platelet membrane glycoprotein IIb/IIIa complex
49. Should use of glycoprotein IIb/IIIa inhibitors to prevent ischemic-complications of angioplasty be dependent on baseline coronary morphology
50. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention
51. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
52. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
53. Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results: The RAPPORT Trial
54. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study
55. Abciximab reduces the need for bail-out stenting during primary angioplasty: The RAPPORT Trial
56. Coronary artery stenting in MI and abciximab: A necessary combination?
57. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
58. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring angioplasty
59. Increased risk of non-Q-wave MI following DCA: Evidence for a platelet dependent mechanism from the EPIC trial
60. Abciximab decreases the incidence and magnitude of non-Q wave myocardial infarction associated with rotational atherectomy
61. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts: EPIC Investigators; Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemie Complications
62. Reduction in complications of angiography with abciximab occurs largely independently of baseline lesion morphology. EPIC and Epilog Investigations
63. Efficacy of abciximab readministration in coronary intervention
64. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: The EPISTENT Investigators; Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
65. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
66. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
67. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II; Integrilin to Minimize Platelet Aggregation, and Coronary Thrombosis-II
68. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
69. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: The RESTORE Investigators (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis)
70. Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I; hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
71. Improved long-term clinical outcomes in unstable angina patients undergoing coronary angioplasty following therapy with tirofiban and heparin
72. Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptifibatide in patients with acute coronary syndromes
73. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
74. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: Evidence for inadequate heparinization
75. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin
76. The use of activated clotting times to monitor heparin therapy during and after interventional procedures
77. All ACTs are not created equal
78. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus
79. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris
80. Heparin therapy during extracorporeal circulation: I. Problems inherent in existing heparin protocols
81. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer
82. Patient-specific heparin dosing during angioplasty
83. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times
84. Heparin resistance prior to cardiopulmonary bypass
85. Angiographically complex lesions are associated with increased levels of thrombin generation and activity following PTCA
86. Preprocedural anticoagulation does not reduce angioplasty heparin requirements
87. Is aggressive heparinization necessary for elective PTCA?
88. Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: Results from the IMPACT-II Trial
89. Predictors of blood loss and bleeding complications after angioplasty
90. Vascular complications after balloon and new device angioplasty
91. Safety of low dose heparin in elective coronary angioplasty
92. Minimal heparinization in coronary angioplasty: How much heparin is really warranted?
93. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty
94. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty
95. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty
96. Subcutaneous heparin in postangioplasty management: Comparative trial with intravenous heparin
97. One year follow-up of the ESSENCE Trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction
98. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
99. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
100. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
101. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
102. Clinical outcomes of bivalirudin for ischemic heart disease
103. The restenosis paradigm revisited: An alternative proposal for cellular mechanisms
104. Cell adhesion molecules in coronary artery disease
105. Clinical trials of restenosis after coronary angioplasty
106. Pharmacological approaches to the prevention of restenosis following angioplasty
107. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention
108. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: A randomized study
109. Effects of low-dose aspirin on restenosis after coronary angioplasty
110. The role of antiplatelet agents in modifiying the extent of restenosis following percutaneous transluminal coronary angioplasty
111. The Frankfurt experience in restenosis after coronary angioplasty
112. Aspirin 500 mg/d is superior to 100 and 40 mg per day for prevention of restenosis following PTCA
113. 2-receptor blockade: A randomized, double-blind, placebo-controlled trial: Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT)
114. Multi-hospital Eastern Atlantic restenosis trial II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty
115. 2 blockade on events after PTCA: M-Heart II
116. Sulotroban during and after coronary angioplasty: A double-blind, placebo controlled study
117. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: A multicenter randomized double-blind placebo-controlled trial
118. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty
119. Beneficial effects of ciprostene in PTCA: A multicenter, randomized, controlled trial
120. Ciprostene for restenosis revisited: Quantitative analysis of angiograms
121. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
122. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents?: The Final ERASER Results
123. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids
124. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty
125. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty
126. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty
127. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty
128. A prospective, randomized, and double-blind trial of the effect of fish oil on the incidence of restenosis following PTCA
129. Fish oil supplements for prevention of restenosis after coronary angioplasty
130. Do fish oils prevent restenosis after coronary angioplasty?
131. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: The EMPAR Study
132. A double-blind, randomized, heparin controlled trial evaluating acute and long-term efficacy of r-hirudin (CGP 39393) in patients undergoing coronary angioplasty
133. Low molecular weight heparin in prevention of restenosis after angioplasty: Results of the enoxaparin restenosis (ERA) trial
134. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty